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Abstract: The authors report the isolation of a Type 1 PRRSV strain from a clinical outbreak of
severe respiratory problems and high fever. Next generation sequencing was used to
determine the complete genome sequence of the isolate (9625/2012). The virus
belongs to a new branch within subtype 1, clade D, containing mostly Spanish
sequences and shows highest similarity to PRRSV Olot/1991 and to the Amervac
vaccine strain. SimPlot analysis performed with the available full-length genome
sequences indicates no evidences of recombination. Mutation analysis of 9625/2012
and the most related strains revealed high proportion of amino acid substitutions in the
putative neutralizing epitopes, suggesting an important role of the selective immune
pressure in the evolution of PRRSV 9625/2012.
Response to Reviewers: The manuscript by Balint et al reports the full genome sequence of an Hungarian
isolate of Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and
phylogenetic analyses. Full genome sequences of PRRSV and studies on genetic
diversity of PRRSV have been already reported; however, there is scarce complete
genome data available for Hungarian PRRSV isolates so the report does provide some
information that could be of interest to those investigators working in the field and
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overall to readers of Archives of Virology. However, the study is more appropriate for a
short report. The article has been shortened to a brief report format, but the overall
structure has not been changed, the methods are concise and reproducible, the result
and discussion sections are only shortened slightly.
Specific comment are detail below:
1. Although the manuscript is well written, there are some inconsistencies in the
abbreviations. For instance, page 3 line 36, it reads INF, the word should be spelled
out completely the first time is used. It seems that the authors are refering to interferon
and as such, this should be clear. If this is the case, the abbreviated form can be used
in the discussion section, instead of the word "interferon." We have doublechecked the
text for such inconsistencies, and the abbreviations are explained when necessary.
2. Phylogenetic trees should included an outgroup to obtain appropriate distances and
to be more informative. We changed the phylogenetic tree by including acc. numbers,
and marking our strain. Probably it was not highlighted enough but an outgroup (Type
2 reference strain VR2332) was already included in the original tree, and was also
indicated in the text. We did not change that.
3. Some of the tables (primers, genbank accession etc) can be ommited. Genbank
accession number information can be easily included in the phylogenetic tree.
Genbank accession numbers were added to the phylogenetic tree, and contents of
table 3 and 4 were added to the text. In our opinion the table descscibing the primers
used for sequencing can not be omitted as it will be very confusing to list all the primer
names, sequences and attachment sites in the text. Former Figure 1, showing SimPlot
results has been omitted, as it shows no evidences of recombination, as it is basically a
negative test, thus the results are described in the text.
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The manuscript by Balint et al reports the full genome sequence of an Hungarian 
isolate of Porcine Reproductive and Respiratory Syndrome virus (PRRSV) and 
phylogenetic analyses. Full genome sequences of PRRSV and studies on genetic 
diversity of PRRSV have been already reported; however, there is scarce 
complete genome data available for Hungarian PRRSV isolates so the report does 
provide some information that could be of interest to those investigators working 
in the field and overall to readers of Archives of Virology. However, the study is 
more appropriate for a short report. The article has been shortened to a brief 
report format, but the overall structure has not been changed, the methods are 
concise and reproducible, the result and discussion sections are only shortened 
slightly. 
Specific comment are detail below: 
1. Although the manuscript is well written, there are some inconsistencies in the 
abbreviations. For instance, page 3 line 36, it reads INF, the word should be 
spelled out completely the first time is used. It seems that the authors are 
refering to interferon and as such, this should be clear. If this is the case, the 
abbreviated form can be used in the discussion section, instead of the word 
"interferon." We have doublechecked the text for such inconsistencies, and the 
abbreviations are explained when necessary. 
2. Phylogenetic trees should included an outgroup to obtain appropriate 
distances and to be more informative. We changed the phylogenetic tree by 
including acc. numbers, and marking our strain. Probably it was not highlighted 
enough but an outgroup (Type 2 reference strain VR2332) was already included 
in the original tree, and was also indicated in the text. We did not change that. 
3. Some of the tables (primers, genbank accession etc) can be ommited. 
Genbank accession number information can be easily included in the 
phylogenetic tree. Genbank accession numbers were added to the phylogenetic 
tree, and contents of table 3 and 4 were added to the text. In our opinion the 
table descscibing the primers used for sequencing can not be omitted as it will be 
very confusing to list all the primer names, sequences and attachment sites in 
the text. Former Figure 1, showing SimPlot results has been omitted, as it shows 
no evidences of recombination, as it is basically a negative test, thus the results 
are described in the text. 
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Abstract  
 
The authors report the isolation of a Type 1 PRRSV strain from a clinical outbreak of severe 
respiratory problems and high fever. Next generation sequencing was used to determine the 
complete genome sequence of the isolate (9625/2012). The virus belongs to a new branch 
within subtype 1, clade D and shows the highest similarity to PRRSV Olot/1991 and to the 
Amervac vaccine strain. Mutation analysis of 9625/2012 indicates no evidences of 
recombination and it revealed high proportion of amino acid substitutions in the putative 
neutralizing epitopes, suggesting an important role of the selective immune pressure in the 
evolution of PRRSV 9625/2012. 
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Porcine Reproductive and Respiratory Syndrome (PRRS) is characterized by reproductive and 
respiratory symptoms, reductions in growth performance and increased mortality in young 
pigs. The etiological agent, Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) 
belongs to the Arterivirus genus within the Arteriviridae family [1], and its strains are divided 
into two major genotypes. Type 1 viruses are related to the early European isolates while 
Type 2 genotype viruses are related to the original North American strains. Recent data show 
that significant genetic variability can occur not only between but also within genotypes [2]. 
Excessive variability among Type 1 strains led to the introduction of four distinct subtypes 
[3].  
 The genetic variability may correspond to the wide range of symptoms extending from 
lack of clinical signs to fatal disease. Highly virulent PRRSV strains of both genotypes have 
been isolated from severe clinical cases from all over the world [4]. Type 1 subtype 3 strains 
‘Lena’ and ‘SU1-bel’ induced increased clinical pathological effects in challenge models [5, 
6]. 
 Multiple genomic regions are responsible for the immunological behaviour and the 
virulence of the PRRSV and this fact underlines the significance of full-length genome 
sequencing. Several studies have confirmed the role of non-structural proteins of PRRSV in 
the modulation of host immune reactions mainly by blocking type I INF (interferon) 
responses of the innate immunity [7, 8]. It was shown that GP5, encoded by ORF5, contains 
B-cell neutralizing epitope, with the presence of multiple glycosylation sites and similarly to 
other Arteriviruses, an immunodominant decoy epitope is located in its proximity [9, 10]. T-
cell epitopes have also been identified on both the GP5 and the N protein (encoded by ORF7) 
by in silico prediction and ex vivo evaluation [11].  
Severe respiratory disease with high fever was observed in a non-vaccinated, 
originally PRRS-free fattening herd of 2500 animals (aged 4–5 months) in Eastern Hungary 
during 2012. The symptoms were resistant to antibiotic treatment, and in prolonged cases, 
posterior paresis and skin haemorrhages were observed. Despite the high (90%) morbidity, 
mortality remained at low level (0.2%). Thorough diagnostic examinations detected the 
presence of PRRSV in the clinical specimens originated from the infected herd. 
The aim of the present study was to determine the full-length genome sequence of the 
PRRSV strain isolated from the aforementioned outbreak and to make an attempt to identify 
putative genetic markers contributing to the severe clinical disease, and to perform 
epidemiological investigations to reveal the origin of the strain. 
Detailed diagnostic examinations of five perished pigs originating from the infected 
herds were performed, based on standard protocols of the National Food Chain Safety Office, 
Veterinary Diagnostic Directorate, Budapest, Hungary. For PRRSV detection, a real time 
PCR assay was executed as described earlier [12], whilst for sequencing of ORF5 and ORF7, 
primer pairs described by Balka et al. [13] were applied.  
 Major respiratory viral and bacterial swine pathogens like classical and African swine 
fever, SIV, ADV, PCV-2, Actinobacillus pleuropneumoniae, Salmonella choleraesuis, 
Streptococcus suis were tested according to the current protocols of the World Organisation 
for Animal Health [14]. Mycoplasma hyopneumoniae was tested by PCR, according to 
Stemke et al. [15]. 
 Culture of porcine alveolar macrophages (PAMs) was prepared according to the OIE 
Manuals [14]. Lung tissue homogenates of PRRSV 9625/2012 were prepared with Tissue 
Lyser (Qiagen, Hilden, Germany) in sterile phosphate-buffered saline (PBS) containing 
antibiotics and antimycotics, and centrifuged at 5000 ×g for 10 min. Cell-free supernatants 
were aliquoted and stored at –80°C for inoculation and RNA isolation. PAMs were inoculated 
with 100 μl of supernatant and incubated for five days.  
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RNA was isolated with QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) and 
cDNA was generated using Superscript III First-Strand Synthesis System for RT-PCR 
(Invitrogen, Carlsbad, CA, USA) kit and a T20 primer, according to the protocol of the 
manufacturer.  
The genome of PRRSV 9625/2012 was amplified in six overlapping parts, using The 
Phusion II HotStart PCR kit (Thermo Scientific, Waltham, MA, USA), in 25 μl final volume 
with 1 μl of cDNA template, in 1x GC buffer in the presence of 4% DMSO. Amplification 
was performed using the following gradient PCR programme: 98°C 1’, 35 × [98°C 20”, 54-
72°C (gradient ramp: 2°C) 20”, 72°C 5’], 72°C 5’. The primer pairs used for the amplification 
of the different fragments are listed in Table 1. For determination of both ends of the genome, 
the 5′ RACE System for Rapid Amplification of cDNA Ends, version 2.0 (Invitrogen, 
Carlsbad, CA, USA) as well as a forward ORF7 primer [13] and the T20 primer were applied.  
An equimolar mixture of the overlapping PRRSV PCR products was used as template 
for next generation sequencing. Sequencing was carried out on a 316 Chip using the Ion 
Torrent semiconductor sequencing equipment (Ion Personal Genome Machine® (PGMTM); 
Life Technologies) according to the manufacturer’s recommendation. Sequences were 
assembled and aligned with the SeqMan Ngen software (Lasergene, Madison, WI, USA). 
MEGA software v.5.1 [16] was used to align DNA and protein sequences and to build 
a phylogenetic reconstruction. Neighbor-joining algorithm was implemented with the 
Kimura-2 parameters model using a transition-to-translation ratio of 2.0. The topology of 
trees was confirmed by 1000 bootstrap replicates. The SimPlot programme [17] was applied 
for visualizing similarity along the whole genome. Potential N-linked glycosylation sites 
(score >0.5) were predicted by the NetNGlyc 1.0 Server [18]. 
 The presence of PRRSV and Mycoplasma hyopneumoniae in the five investigated pigs 
was confirmed by real-time PCR and conventional PCR, respectively. The absence of other 
respiratory and generalized bacterial infection was diagnostically confirmed by bacterial 
cultivation, serology, and PCR.  
The full length sequence of PRRSV 9625/2012 was 15098 nt long (Genbank Acc. No: 
KJ415276). At genome level, the overall nucleotide identity was 96%, 95%, 92% and 58% 
with PRRSV strains Amervac MLV, Olot/1991, Lelystad (acc.: M96262) and the Type 2 
prototype strain VR-2332 (acc.: U87392), respectively.  
 PRRSV 9625/2012 showed the closest similarity to the vaccine strain Amervac MLV 
(613 nucleotide change with no deletion/insertion) raising the possibility of direct 
descendancy between the two viruses, which could have been facilitated by viral transmission 
after vaccination.  
No signs of recombination with Amervac MLV or other PRRSV strains were observed 
according to the SimPlot analysis (data not shown) indicating the lack of such an event in the 
evolution of PRRSV 9625/2012. Throughout the whole genome the Amervac MLV and 
Olot/91 strains exhibited the closest similarity, ranging between 86–99%, but never reached 
100%. Nucleotide similarity fluctuated between 79–98% and 0–73% with PRRSV type 1 
Lelystad and Type 2 VR-2332 reference strains, respectively.  
The phylogenetic tree using ORF5 sequences from a selection of Type 1 strains and 
VR-2332 as outgroup revealed that PRRSV 9625/2012 is a Type 1, subtype 1 virus within 
Clade D, defined by Shi et al. 2010 [5]. The closest (96%) nucleotide identity was shared with 
Spanish and other, MLV-like strains (Fig. 1) that have already been present in Hungary for a 
decade [13], but our strain seems to represent a previously unknown evolutionary branch 
within this clade. 
The analysis of the putative amino acid (aa) sequences of the aforementioned three 
strains revealed that the most aa variations are found in Nsp1 (93% identity, 96–97% 
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similarity) and Nsp2 (93% identity, 94–95% similarity). The structural proteins of PRRSV 
9625/2012 showed 94–98% identity with Amervac MLV and Olot/1991.  
We compared the antigenic regions (ARs) within GP2, GP3, GP4 and GP5 proteins of 
PRRSV 9625/2012 with Amervac MLV and Olot/1991, since these proteins are the main 
targets for neutralizing antibodies. 
 In the two neutralizing epitopes AR II and AR IV of GP2 [9, 19], one-one aa 
substitutions were found, respectively (Fig. 2a). Additionally, two aa substitutions were also 
detected right upstream of AR II. In the non-neutralizing ARs I, III and V, two, one and zero 
aa substitutions were observed, respectively. In the non-antigenic part of the protein, only 
three aa differences were found (Fig 2a). 
 In the two neutralizing epitopes AR I and AR VIII [19, 20] of GP3, two and three aa 
substitutions were found, respectively, whilst the non-neutralizing AR II contained two 
mutations (Fig. 2b). The non-antigenic part of the protein contained five aa substitutions. 
 Four aa substitutions were found in the neutralizing epitope AR I of GP4 [19, 21], 
while three mutations were observed in the non-immunogenic part of the protein (Fig. 2c).  
 In the neutralizing epitope of Type I PRRSV GP5 [22], one aa substitution was found. 
AR I, the main epitope targeted by neutralizing antibodies in Type II strains [10], but non-
neutralizing epitope in the case of Type I PRRSV [19, 23], demonstrated a single aa 
substitution. The other non-neutralizing epitopes of GP5, AR II and AR IV contain no aa 
mutations. The non-antigenic region of the protein contained four aa substitutions (Fig. 2d). It 
is striking that a disproportionally large number of the aa changes in ORF2-4 occur in known 
B cell epitopes which suggests a strong immunological pressure in these regions. 
The GP5 of isolate 9625/2012 contained three putative N-glycosylation sites at aa 37, 
46 and 53. That of PRRSV Amervac MLV also contained three at 35, 46 and 53, while GP5 
of Olot/1991 had only two putative N-glycosylation sites at aa 46 and 53. 
 Both PRRSV genotypes change at a rate of 0.5–1% per year in the field [24]. The 96% 
similarity observed between 9625/2012 and Olot/1991/Amervac MLV may equate to 4–8 
years of changing in field. Since 2004, strains with 98–99% similarity to the vaccine strain 
have been identified in herds vaccinated with Amervac MLV [13, Bálint, personal data]. 
However, PRRSV 9625/2012 had higher genetic distance from the vaccine strain, and 
occurred in a fattener farm that has never been vaccinated against PRRS. Yet the most 
plausible explanation of the origin of PRRSV 9625/2012 is that it descended from Amervac 
MLV or an Olot/1991-like, unidentified strain between 2004 and 2008, and it 
circulated/evolved without being identified in Hungary until its appearance in 2012. Another 
explanation could be that it was newly introduced to Hungary in 2012 as a new PRRSV 
variant from an unidentified source.  
 Analysis of the putative amino acid sequence revealed the presence of relatively high 
aa differences in Nsp1 and Nsp2 between 9625/2012 and related viruses. This phenomenon 
may correspond to the fact that these proteins are involved in the blockage of the type I IFN 
synthesis and signalling pathway [25]. Furthermore, nsp2 is the viral protein containing the 
highest frequency in B cell epitopes [26]. The amino acid sequence variability in this protein 
is high both within and between genotypes [27], and changes including deletions in these 
parts of the genome might have an influence on the pathogenicity of the strains [10]. 
 The two aa substitutions in the neutralizing epitopes and the three aa differences in the 
non-neutralizing ARs, versus the three aa substitutions in the non-antigenic part of the GP2 
protein suggest the role of selective immune pressure in the development of this strain. Those 
variants that show bigger differences on the antigenic regions compared to the original strains 
might have the ability to avoid or decrease the efficacy of neutralizing antibody attachment. 
Similar tendencies have already been identified in PRRSV circulating in Hungary [13]. The 
two aa substitutions right upstream of AR II suggest that this region might be extended N-
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terminally, considering that its terminal border was mapped originally with a precision of 
about two amino acids [9].  
 It has been long suspected that an ‘epitope site’ covering ARs GP3-I and GP3-II is 
involved in functional interactions with the host cell [9, 28] but it was only recently proven 
that antibodies against AR I have neutralizing capacity [19]. The three aa substitutions in AR 
I and AR II, as well as the three found in the neutralizing epitope of AR VIII, may also reflect 
immunogenic pressure.  
 In GP4, a neutralizing epitope is present in Type I PRRSV from aa 57 to 68 [21] 
within AR I [19]. The three aa substitutions found within this sequence confirm that this 
region is under antibody-mediated pressure in vitro and in vivo [29]. Whether these 
substitutions contribute to the generation of an escape mutant that is not cross-neutralized 
with PRRSV Amervac MLV or Olot/1991 is still unknown. 
 GP5 has been considered to be the main target for virus neutralizing antibodies in 
North American PRRSV strains [10]. A neutralizing epitope has been identified at positions 
37–45 [10], but this epitope proved to be non-neutralizing in the case of Type I PRRSV [19, 
23]. The neutralizing epitope in Type I GP5 is located upstream of this epitope from residues 
29 to 35 [22]. The three amino-acid substitutions present from aa 36–38 spanning the two 
aforementioned epitopes may suggest a role of selective immunological pressure in the 
sequence change.  
  A plausible explanation for the severe clinical signs and pathological lesions 
observed during the outbreak could be the presence of a concurrent Mycoplasma 
hyopneumoniae infection. Previous studies have shown an increase in the severity of the 
pneumonia induced by dual, compared to single infection either with Mycoplasma 
hyopneumoniae and PRRSV [30]. Moreover, increased production of proinflammatory 
cytokines have been observed following dual inoculation with these pathogens when 
compared to single infections [31]. 
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Table and Figure legends 
 
Table 1. Oligonucleotide primers used for RT-PCR amplification of PRRSV 9625/2012. 
 
Figure 1. Phlyogenetic analysis of the ORF5 coding region of PRRSV 9625/2012 using the 
neighbour-joining method and adding VR-2332 Type 2 reference strain as outgroup. The 
topology of the tree was confirmed by 1000 bootstrapping steps.  
 
Figure 2. Alignment of a, ORF2; b, ORF3; c, ORF4 and d, ORF5. Antigenic regions are 
shaded. Underlined sequences represent neutralizing epitopes. 
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Figure 2. Alignment of a, ORF2; b, ORF3; c, ORF4 and d, ORF5. Antigenic regions are shaded. Underlined sequences represent neutralizing epitopes. 
 
a, 
                  AR I                             AR II                                                AR III 100 
9625/2012 : MQWGHCGVKSASCSWTPSLSSLLVWLTLSFFSPYCSGSPSQDGYWSFFSEWFAPRFSVRALPFTLPNYRRSYEGLLPNCRPDVPQFAFKHPLGMFWHMRV 
AMERVAC : ....Y....L................I...SL...L.....................................S...................IL..... 
OLOT/1991 : ....Y....L................I...SL...L..........S..........................S...................IL..... 
                                                                                                                  
                                AR IV                                                                          200 
9625/2012 : SHLIDEMVSRRIYRTMEHSGQAAWKQVVSEATLTKLSGLDIVTHFQHLAAVEADSCRFLSSRLVMLKNLAVGNVSLQYNTTLDRVELIFPTPGTRPKLTD 
AMERVAC : ...................S...............................................................H................ 
OLOT/1991 : ...................S...............................................................H................ 
                                                                                                                  
                 AR V                            240 
9625/2012 : FRQWLVSVHASIFSSVASSVTLFIVFWLRIPAVRYVFGFHWPTATHHSS 
AMERVAC : ................................................. 
OLOT/1991 : ................................X................ 
 
b, 
                                                                                                                                            AR I                              AR II                 100 
9625/2012 : MARQCTRFHFFLCGFICYLVHSVLATNSSRTLCFWFPLAHGNTSFELTINYTICMPCPTSQAAKQRLEPGRNMWCRIGQDRCEERDHDELSMSIPSGYEN 
AMERVAC : ..H..A...................S...............................S.....S..............H..................... 
OLOT/1991 : ..H..A...................S...X...........................S.....S..............H..................... 
                                                                                                                  
                                                                                                                  
                                                                                                               200     
9625/2012 : LKLEGYYAWLAFLSFSYAAQSHPELFGIGNVSRVFVDKRHQFICAEHDGQNSTISTEHNISASYAVYYHHQIDGGNWFHLEWLRPFFSSWLVLNISWFLR 
AMERVAC : ....................F...................................G.....L..................................... 
OLOT/1991 : ....................F...................................G.....L..................................... 
                                                                                                                  
                                                            AR VIII   260       
9625/2012 : RSPVSPVSRRIYQILRPTRPRLPVSWSFRTSIVSDLTGSQQRKRLFPSENRLNVARPSAFPSTSR 
AMERVAC : ............................................P....S.P......V....L. 
OLOT/1991 : ............................................P....S.P......V....L. 
 
Figure
Click here to download Figure: Fig2.doc 
c, 
                                                                                                                                                    AR I                                 100 
9625/2012 : MAAAILFLLVGAQYLMVSEAFACKPCFSTHLSDIKTNTTAAAGFLVLQDINCLRPHGVPTAQETLSIRKPSQCREAVGIPQYITITANVTDESYLYNADL 
AMERVAC : .........A..................................M.............S.....I.FG................................ 
OLOT/1991 : .........A..................................M.............S.....I.FG................................ 
                                                                                                                  
                                                                                         180     
9625/2012 : LMLSACLFYASEMSEKGFKVIFGNVSGVVSACVNFTDYVAHVIQHTQQHHLAIDHIRLLHFLTPSTMRWATTIACLFAILLAI 
AMERVAC : ...................................................V............................... 
OLOT/1991 : ...................................................V............................... 
 
d, 
                                                   AR I                                                        100 
9625/2012 : MRCSHKLGRFLTLHSCFWWLFLLCTGLSWSFVDGSDNSSTYQYIYNLTICELNGTDWLSSHFDWAVETFVLYPVATHILSLGFLTTSHFFDALGLGAVST 
AMERVAC : .......E....P.....................N.S..................E..P......................................... 
OLOT/1991 : .......E....P.....................NGB..................E..P......................................... 
                                                                                                                  
                                                             AR II             AR III                   AR IV  200 
9625/2012 : TGFIGGRYVLSSVYGACAFAALVCFVIRAAKNCMACRYARTRFTNFIVDDRGRIHRWKSPIVVEKLGKAEVGGDLVTIKHVVLEGVKAQPLTRTSAEQWEA 
AMERVAC : ...V................................................................................................. 
OLOT/1991 : ...V.................................................V............................................... 
 
 
Table 1. Oligonucleotide primers used for RT-PCR amplification of PRRSV 
9625/2012 
 
Primer Sequence Position 
PR_EU_15F  ATTCCCCCTACATACACGACAC 15-36 
PR_AVAC_2477F CTCGGACTCCATGAAAGGAA 2477-2496 
PR_EU_4719F CCATGGTGTTCAAATCCTTTTT 4719-4740 
PR_AVAC_9300F TGTGGGAGAAACTGAAAAGTCA 9300-9321 
PR_AVAC_11818F TAAAATTAGCCAGCTGTTCGTG 11818-11839 
PR_AVAC_2902R ATGATAGAGCTGGATTCGGAAA 2902-2881 
PR_AVAC_5337R CGGTGTTAAGGCAGGGTTTATG  5337-5316 
PR_AVAC_9859R CATAGTCTGATGGGTGGGTGTA 9859-9838 
PR_AVAC_12552R TTGATGGTTAGCTCGAATGATG  12552-12531 
Pr15047R  T(24)AATTTCGGTCACATGGTTCCTGCCTG 15098-15073 
 
Table
